We are live on
!
Find out more
SIC
Starr International Company Portfolio holdings
AUM
$19.9M
1-Year Est. Return
39.69%
This Fund
S&P 500
This Quarter
Est. Return
+0.04%
1 Year Est. Return
-39.69%
3 Year Est. Return
-26.08%
5 Year Est. Return
-43.79%
10 Year Est. Return
-39.24%
AUM
$22.4M
AUM Growth
+$9.24M
(+70%)
Cap. Flow
+$9.99M
Cap. Flow
% of AUM
44.6%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
2
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$5.17M |
| 2 |
Moderna
MRNA
|
+$4.67M |
| 3 |
Bain Capital Specialty
BCSF
|
+$142K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.24% |
| 2 | Financials | 42.76% |
Similar funds
DOS
AA
LUGPI
CVSCT
RCP
IVM
CCFM
VNB
Starr International Company's Q3 2020 Portfolio in Review
As of Q3 2020, Starr International Company held 5 positions worth $22.4M, up 70% from $13.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Starr International Company deployed $9.99M of net new capital in Q3 2020, opening 2 new positions and adding to 1 existing holding. Its largest new stake was AstraZeneca: 46,500 shares worth $5.1M.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 21% a quarter earlier, followed by Financials.
- Starr International Company's largest Q3 2020 buy was AstraZeneca: 46,500 shares worth $5.1M.
- Starr International Company added most to Bain Capital Specialty in Q3 2020, an estimated $142K increase.
- Starr International Company's ten largest holdings make up 100% of its $22.4M portfolio in Q3 2020.
- Starr International Company opened 2 new positions and closed 0 in Q3 2020.
- Starr International Company's portfolio value rose 70% quarter-over-quarter to $22.4M.
Based on Starr International Company's 13F filing for Q3 2020, filed 9 Oct 2020.